Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer.

@article{Kono2009VaccinationWM,
  title={Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer.},
  author={Koji Kono and Yoshiki Mizukami and Yataro Daigo and Atsushi Takano and Ken Masuda and Koji Yoshida and Takuya Tsunoda and Yoshihiko Kawaguchi and Yusuke Nakamura and Hideki Fujii},
  journal={Cancer science},
  year={2009},
  volume={100 8},
  pages={1502-9}
}
We previously identified three novel HLA-A24-restricted epitope peptides, which were derived from three cancer-testis antigens, TTK protein kinase (TTK), lymphocyte antigen 6 complex locus K (LY6K), and insulin-like growth factor (IGF)-II mRNA binding protein 3 (IMP-3), as targets for cancer vaccination against esophageal squamous cell carcinoma (ESCC). To examine the safety, immunogenicity, and antitumor effect of vaccine treatment using a combination of these three peptides, 10 HLA-A2402… CONTINUE READING